about
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistantSunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules.PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies.Post-docetaxel therapy in castration resistant prostate cancer - the forest is growing in the desert.Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.Visceral disease in castration-resistant prostate cancer.Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.Clinical and pathological features of primary neuroectodermal tumor/Ewing sarcoma of the kidney.Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials.Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.Clinical and pathological features of primary renal synovial sarcoma: analysis of 64 cases from 11 years of medical literature.External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with AbirateroneSunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysisImmune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches
P50
Q26851177-26831E5A-661E-4057-B9B8-A406DDC8FE38Q33424769-0AC104E7-B15D-4B1A-8A29-F0C78D3D2A1FQ34310067-2B709A51-7B1D-4BD7-9114-6DEE9CCECD18Q35540013-BC332E4B-F2D4-4ABD-B988-B123F5FB6B3CQ37462283-1BAB0C8C-F236-4D58-9988-5C57B114CA5DQ38263563-D58DACF7-87C7-4B5A-B4AD-CE4B613EFE67Q38475150-49BC8217-87FF-4C51-830D-ADEF2E96E8C0Q38870960-94869C6E-D7EC-4FC7-9DF3-BC0564D81E53Q38956651-485F719D-06E8-466B-BF5A-1FE6757CC099Q42586178-3278C594-D420-4CA7-9E91-0B1D2B790205Q42758807-342075E2-026D-4FE0-AF4E-C05B161D101EQ43019633-163423DA-C35D-4BE4-A985-625203DFB5F4Q44838662-49FFD43E-AEB6-4475-AD9F-586E58D4BC8FQ46591789-72AA84B6-3C8F-4D9A-9B2E-8BE5171AF79FQ47931535-58A0C91C-5FD2-48C8-9A4B-18FD6E013573Q47977332-DD5DFBB4-F130-4DC9-B8C9-6D11C7A3C999Q57693891-A65C63E2-130C-4D81-941F-F0DF85FE3B3CQ86940812-973F90EE-37B1-4EBD-B58B-5B2790E576BDQ92305209-85771D16-88E1-49A9-863E-E8268000B093
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Amelia Altavilla
@ast
Amelia Altavilla
@en
Amelia Altavilla
@es
Amelia Altavilla
@nl
type
label
Amelia Altavilla
@ast
Amelia Altavilla
@en
Amelia Altavilla
@es
Amelia Altavilla
@nl
prefLabel
Amelia Altavilla
@ast
Amelia Altavilla
@en
Amelia Altavilla
@es
Amelia Altavilla
@nl
P106
P1153
49661042800
P21
P31
P496
0000-0002-1598-9451